AdultPediatricDosage Forms & Strengths capsule 5mg 10mg 25mg 50mg Schizophrenia Initial: 10-25 mg PO q12hr Maintenance: 60-100 mg/day divided q6-12hr; not to exceed 250 mg/day Dosing Considerations For maintenance therapy, reduce dosage to lowest level compatible with symptom control; many patients have been maintained satisfactorily at dosages in the range of 20 to 60 mg dailyNot recommendedInteraction CheckerEnter a drug name and loxapineNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (1)amisulprideamisulpride, loxapine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.Serious - Use Alternative (23)apomorphineloxapine decreases effects of apomorphine by pharmacodynamic antagonism. Contraindicated.benzhydrocodone/acetaminophenbenzhydrocodone/acetaminophen, loxapine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.bromocriptineloxapine decreases effects of bromocriptine by pharmacodynamic antagonism. Contraindicated.cabergolineloxapine decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated.calcium/magnesium/potassium/sodium oxybatesloxapine, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.dopamineloxapine decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.fentanylfentanyl, loxapine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fentanyl intranasalfentanyl intranasal, loxapine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fentanyl transdermalfentanyl transdermal, loxapine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fentanyl transmucosalfentanyl transmucosal, loxapine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.hydrocodonehydrocodone, loxapine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.levodopaloxapine decreases effects of levodopa by pharmacodynamic antagonism. Avoid or Use Alternate Drug.lisurideloxapine decreases effects of lisuride by pharmacodynamic antagonism. Contraindicated.mefloquinemefloquine increases toxicity of loxapine by QTc interval. Avoid or Use Alternate Drug. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.methyldopaloxapine decreases effects of methyldopa by pharmacodynamic antagonism. Contraindicated.metoclopramide intranasalloxapine, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.loxapine increases toxicity of metoclopramide intranasal by pharmacodynamic synergism. Avoid or Use Alternate Drug. Potential for additive effects, including increased frequency and severity of tardive dyskinesia, other extrapyramidal symptoms, and neuroleptic malignant syndrome.olopatadine intranasalloxapine and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. pramipexoleloxapine decreases effects of pramipexole by pharmacodynamic antagonism. Contraindicated.ropiniroleloxapine decreases effects of ropinirole by pharmacodynamic antagonism. Contraindicated.safinamideloxapine decreases effects of safinamide by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Dopamine antagonists may decrease safinamide effects and exacerbate Parkinson disease symptoms.selinexorselinexor, loxapine. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.sodium oxybateloxapine, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.sufentanil SLsufentanil SL, loxapine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.Monitor Closely (268)abobotulinumtoxinAabobotulinumtoxinA increases effects of loxapine by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.aclidiniumaclidinium decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.aclidinium decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor.loxapine increases effects of aclidinium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.acrivastineacrivastine and loxapine both increase sedation. Use Caution/Monitor.albuterolloxapine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.alfentanilalfentanil and loxapine both increase sedation. Use Caution/Monitor.almotriptanalmotriptan, loxapine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).alprazolamalprazolam and loxapine both increase sedation. Use Caution/Monitor.amifampridineloxapine increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.amitriptylineloxapine and amitriptyline both increase sedation. Use Caution/Monitor.amobarbitalamobarbital and loxapine both increase sedation. Use Caution/Monitor.amoxapineloxapine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.loxapine and amoxapine both increase sedation. Use Caution/Monitor.anticholinergic/sedative combosanticholinergic/sedative combos decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.anticholinergic/sedative combos decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor.loxapine increases effects of anticholinergic/sedative combos by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.apomorphineloxapine and apomorphine both increase sedation. Use Caution/Monitor.arformoterolloxapine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.aripiprazolearipiprazole and loxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.aripiprazole and loxapine both increase sedation. Use Caution/Monitor.armodafinilloxapine increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.asenapineasenapine and loxapine both increase sedation. Use Caution/Monitor.asenapine transdermalasenapine transdermal and loxapine both increase sedation. Use Caution/Monitor.atracuriumatracurium decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.atracurium decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor.loxapine increases effects of atracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.atropineatropine decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.atropine decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor.loxapine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.atropine IV/IMloxapine increases effects of atropine IV/IM by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.atropine IV/IM decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.atropine IV/IM decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor.avapritinibavapritinib and loxapine both increase sedation. Use Caution/Monitor.azelastineazelastine and loxapine both increase sedation. Use Caution/Monitor.baclofenbaclofen and loxapine both increase sedation. Use Caution/Monitor.belladonna alkaloidsbelladonna alkaloids decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.belladonna alkaloids decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor.loxapine increases effects of belladonna alkaloids by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.belladonna and opiumbelladonna and opium and loxapine both increase sedation. Use Caution/Monitor.belladonna and opium decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.belladonna and opium decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor.loxapine increases effects of belladonna and opium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.benperidolbenperidol and loxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.benperidol and loxapine both increase sedation. Use Caution/Monitor.benzhydrocodone/acetaminophenbenzhydrocodone/acetaminophen and loxapine both increase sedation. Use Caution/Monitor.benzphetamineloxapine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.benztropineloxapine increases effects of benztropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.brexanolonebrexanolone, loxapine. Either increases toxicity of the other by sedation. Use Caution/Monitor.brexpiprazolebrexpiprazole and loxapine both increase sedation. Use Caution/Monitor.brimonidinebrimonidine and loxapine both increase sedation. Use Caution/Monitor.brivaracetambrivaracetam and loxapine both increase sedation. Use Caution/Monitor.brompheniraminebrompheniramine and loxapine both increase sedation. Use Caution/Monitor.buprenorphinebuprenorphine and loxapine both increase sedation. Use Caution/Monitor.buprenorphine buccalbuprenorphine buccal and loxapine both increase sedation. Use Caution/Monitor.buprenorphine subdermal implantbuprenorphine subdermal implant and loxapine both increase sedation. Use Caution/Monitor.buprenorphine transdermalbuprenorphine transdermal and loxapine both increase sedation. Use Caution/Monitor.buprenorphine, long-acting injectionloxapine increases toxicity of buprenorphine, long-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate.buprenorphine, long-acting injection and loxapine both increase sedation. Use Caution/Monitor.butabarbitalbutabarbital and loxapine both increase sedation. Use Caution/Monitor.butalbitalbutalbital and loxapine both increase sedation. Use Caution/Monitor.butorphanolbutorphanol and loxapine both increase sedation. Use Caution/Monitor.caffeineloxapine increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.carbamazepineloxapine will increase the level or effect of carbamazepine by decreasing metabolism. Modify Therapy/Monitor Closely. Monitor plasma levels when used concomitantlycarbinoxaminecarbinoxamine and loxapine both increase sedation. Use Caution/Monitor.carisoprodolcarisoprodol and loxapine both increase sedation. Use Caution/Monitor.chloral hydratechloral hydrate and loxapine both increase sedation. Use Caution/Monitor.chlordiazepoxidechlordiazepoxide and loxapine both increase sedation. Use Caution/Monitor.chlorpheniraminechlorpheniramine and loxapine both increase sedation. Use Caution/Monitor.chlorpromazinechlorpromazine and loxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.chlorpromazine and loxapine both increase sedation. Use Caution/Monitor.chlorzoxazonechlorzoxazone and loxapine both increase sedation. Use Caution/Monitor.cinnarizinecinnarizine and loxapine both increase sedation. Use Caution/Monitor.cisatracuriumcisatracurium decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.cisatracurium decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor.loxapine increases effects of cisatracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.clemastineclemastine and loxapine both increase sedation. Use Caution/Monitor.clomipramineloxapine and clomipramine both increase sedation. Use Caution/Monitor.clonazepamclonazepam and loxapine both increase sedation. Use Caution/Monitor.clonidineclonidine, loxapine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.clorazepateclorazepate and loxapine both increase sedation. Use Caution/Monitor.clozapineclozapine and loxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.clozapine and loxapine both increase sedation. Use Caution/Monitor.codeinecodeine and loxapine both increase sedation. Use Caution/Monitor.cyclizinecyclizine and loxapine both increase sedation. Use Caution/Monitor.cyclizine decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.cyclizine decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor.loxapine increases effects of cyclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.cyclobenzaprinecyclobenzaprine and loxapine both increase sedation. Use Caution/Monitor.cyproheptadinecyproheptadine and loxapine both increase sedation. Use Caution/Monitor.dantrolenedantrolene and loxapine both increase sedation. Use Caution/Monitor.daridorexantloxapine and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance